205 related articles for article (PubMed ID: 15695801)
1. Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
Goldenberg DM; Sharkey RM
J Nucl Med; 2005 Feb; 46(2):383-4. PubMed ID: 15695801
[No Abstract] [Full Text] [Related]
2. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
de Nully Brown P; Jurlander J; Lindén O; Hansen M
Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy of Non-Hodgkin's lymphoma.
Britton KE
J Nucl Med; 2004 May; 45(5):924-5. PubMed ID: 15136647
[No Abstract] [Full Text] [Related]
4. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy for Non-Hodgkin's Lymphoma.
Rao AV; Akabani G; Rizzieri DA
Clin Med Res; 2005 Aug; 3(3):157-65. PubMed ID: 16160070
[TBL] [Abstract][Full Text] [Related]
6. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
Bischof Delaloye A; Conti PS; Gisselbrecht C; Gregory SA
Oncologist; 2009; 14 Suppl 2():52-4. PubMed ID: 19819924
[No Abstract] [Full Text] [Related]
7. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
[TBL] [Abstract][Full Text] [Related]
8. [New trends in non-Hodgkin's lymphoma therapy].
Mazur G; Wróbel T; Jurczak W; Butrym A
Postepy Hig Med Dosw (Online); 2006; 60():707-21. PubMed ID: 17245320
[TBL] [Abstract][Full Text] [Related]
9. Durable responses reported with radioimmunotherapy in low-grade non-Hodgkin's lymphoma.
Oncology (Williston Park); 2002 Mar; 16(3):304, 326. PubMed ID: 15046389
[No Abstract] [Full Text] [Related]
10. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
Pauwels EK; Erba P
Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
[TBL] [Abstract][Full Text] [Related]
11. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; O'Donnell RT; Kroger LA; Kukis DL; Meares CF; Goldstein DS; Shen S
Clin Lymphoma; 2000 Sep; 1(2):118-26. PubMed ID: 11707820
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
Kawashima H
ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
Macklis RM
Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond.
Evens AM; Gordon LI
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S11-5. PubMed ID: 15498144
[TBL] [Abstract][Full Text] [Related]
15. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.
Santos ES; Kharfan-Dabaja MA; Ayala E; Raez LE
Leuk Lymphoma; 2006 Dec; 47(12):2453-76. PubMed ID: 17169792
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
Hendrix CS; de Leon C; Dillman RO
Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
[TBL] [Abstract][Full Text] [Related]
17. New strategies in radioimmunotherapy for lymphoma.
Pandit-Taskar N; Hamlin PA; Reyes S; Larson SM; Divgi CR
Curr Oncol Rep; 2003 Sep; 5(5):364-71. PubMed ID: 12895386
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
Meredith RF; Knox SJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
[TBL] [Abstract][Full Text] [Related]
19. Iodine-131 anti-B1 antibody therapy in non-Hodgkin's lymphoma: dosimetry and clinical implications.
Wahl RL
J Nucl Med; 1998 Aug; 39(8 Suppl):1S. PubMed ID: 9708563
[No Abstract] [Full Text] [Related]
20. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma.
Leonard JP; Siegel JA; Goldsmith SJ
Cancer Invest; 2003 Apr; 21(2):241-52. PubMed ID: 12743990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
